Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04673708 Completed - Sexual Behavior Clinical Trials

H - Test Usage in Identification of Sexual Orientation Among People.

Start date: December 11, 2020
Phase: N/A
Study type: Interventional

Using of H - test in identifying the sexual behavior of the human.

NCT ID: NCT04673006 Completed - Clinical trials for Anesthesiologists Who Perform Endotracheal Intubation and Extubation

Risk of Bacterial Exposure to the Anesthesiologist's Face During Intubation and Extubation

Start date: January 8, 2021
Phase:
Study type: Observational

The practice of intubation and extubation is not without risks to the anesthesiologists. Especially, the face of health care worker is the body part most commonly contaminated by splashes and sprays of body fluids. The aim of this study is to determine the incidence of unrecognized exposure to the anesthesiologists' face during endotracheal intubation and extubation. We will perform face shield swab before and after the endotracheal intubation and extubation. All swabs will be cultured for 48 hours and the number of colony forming units before and after the procedures (intubation/extubation) will be compared.

NCT ID: NCT04672941 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Start date: February 16, 2021
Phase:
Study type: Observational

The primary objective of this non-interventional study (NIS) is to evaluate changes within 3 months in quality of life according to health status evaluated with the COPD Assessment Test (CAT) in COPD patients who have recently switched (within one week) from tiotropium monotherapy (Spiriva® Handihaler®) to dual therapy with tiotropium bromide plus olodaterol (Spiolto® Respimat®), in the Greek private and public sector pulmonary offices and clinics.

NCT ID: NCT04672772 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

Start date: December 18, 2020
Phase:
Study type: Observational

Retrospective observational study that aims to collect real world data on the cetuximab plus paclitaxel regimen as first line treatment for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Assignment of a patient to a specific therapeutic strategy has been already decided in the past according to normal routine clinical practice; the decision to prescribe a specific treatment (between January 2012 and December 2018) was clearly dissociated from the decision to include a patient in the present study. The investigators will retrospectively collect the information for 500 patients diagnosed with recurrent and/or metastatic SCCHN treated with a cetuximab plus paclitaxel regimen as first line for unresectable recurrent and/or metastatic disease, starting treatment with the defined cetuximab plus paclitaxel regimen, in 20 hospital members of the "Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC)", who express consent to participate in the study or have not explicitly withheld consent for use of their data. The information from the patients' medical records will be collected through the online database of the TTCC Group.

NCT ID: NCT04671810 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Prospective Observational Study of Long-term Pathogenic Treatment of Elizaria®

NAP
Start date: June 13, 2019
Phase:
Study type: Observational

This is prospective observational study of long-term pathogenic treatment of Elizaria® in patients with paroxysmal nocturnal hemoglobinuria.

NCT ID: NCT04671732 Completed - Clinical trials for Complex Abdominal Aortic Aneurysm, ie. Juxtarenal or Suprarenal Aortic Aneurysms, Treated by Fenestrated Endovascular Aortic Aneurysm Repair or Open Repair

Cost-utility Analysis of Fenestrated Aortic Stents Versus Open Surgery for the Treatment of Complex Abdominal Aortic Aneurysms

ORFEVAR
Start date: March 14, 2021
Phase:
Study type: Observational

Introduction: Complex abdominal aortic aneurysms (CAA) are defined as abdominal aneurysms that are anatomically unsuitable for a standard endovascular repair because of a short infrarenal neck or no infrarenal neck. These CAAA are usually treated either by fenestrated endovascular aortic repair (FEVAR) or open repair (OR). Data comparing these thechniques remain scarce, mainly consisting of systematic reviews based on retrospective studies. Although mid-term and long-term results remain uncertain, FEVAR has gained widespread acceptance in the vascular community. However, this practice is not evidence base. Beyond clinical results, whether FEVAR is cost-effective or not is not demonstrated. A randomized controlled trial comparing FEVAR and OR is unlikely to be conducted since centers have developed specific expertise and practice, and most of surgeons are not keen to randomize patients. Thus, we believe that a prospective comparative multicentric cohort, with a propensity score and minimization of selection, classification and confusion bias is the most realistic way to provide reliable comparative data on cost effectiveness of FEVAR and OR. Overall, 382 patients are expected to be included (159 in each group). Objective: The objective of this prospective non-randomized comparative multicenter cohort study is to compare the cost effectiveness incremental ratio at 36 months of FEVAR and OR for CAAA. Method: Patients with CAAA discussed for FEVAR or OR in 37 french vascular centers in during a two years inclusion period constitute the population study. Preoperative and postoperative clinical and imaging data will are collected prospectively in eCRF forms. QOL before and after treatment is assessed by the E5D5L. The follow-up period is three years. The primary outcome is the Incremental cost-utility ratio (cost/QALY) at 36 months. We plan to minimize indication biases by using a proposensity score (proposnsity score maching and Inverse probablility of treatment weighting) based on clinical and anatomic characteristics. Patient at prohibitive risk for OR are excluded. Patient anatomically unsuitable for FEVAR are also excluded . Conclusion: This study should provided valuable data on cost effectiveness of FEVAR for CAAA. Sub-goup analysis will be also conducted.

NCT ID: NCT04671628 Completed - Anxiety Clinical Trials

Effects of a 2-week Relaxing Music Intervention on Anxiety, Stress, and Gut Symptoms in Aerobic Exercisers

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The objective of the study is to determine the impacts of a 2-week relaxing music intervention on stress, anxiety, and gut symptoms in individuals who regularly perform structured aerobic exercise. Gut symptoms like bloating, reflux, cramping, nausea, etc. are relatively common during prolonged aerobic exercise. In addition, previous research has established that levels of anxiety and stress are associated with a higher occurrence of these gut symptoms. Relaxing music has reduced anxiety in certain populations, but currently, no studies are available on its effects on anxiety, stress, and gut symptoms in people who regularly do aerobic exercise.

NCT ID: NCT04671563 Completed - Clinical trials for Pharmacokinetic of Tenofovir in Healthy Subjects

Pharmacokinetics of Two Formulation of Tenofovir Disoproxil Fumarate

Start date: April 22, 2019
Phase: Phase 4
Study type: Interventional

To evaluate pharmacokinetic profiles of Viproof Film Coated Tablets 300 mg manufactured by Yung Shin Parm. Ind. Co., Ltd., Taiwan and Viread Tablets manufactured by Patheon, Inc. in terms of plasma concentrations of tenofovir after a single oral dose of 300 mg tenofovir disoproxil fumarate in healthy subjects under fasting conditions.

NCT ID: NCT04671472 Completed - GNE Myopathy Clinical Trials

Efficacy Confirmation Study of NPC-09

Start date: February 8, 2021
Phase: Phase 3
Study type: Interventional

GNE myopathy is a distal myopathy that is thought to be caused by a mutation in the GNE gene that encodes an enzyme in the biosynthetic process of aceneuramic acid (typical sialic acid). The investigators will examine the efficacy and safety of aceneuramic acid (SA-ER tablets) 6g daily for 48 weeks in patients with GNE myopathy in a placebo-controlled, double-blind, controlled trial.

NCT ID: NCT04671290 Completed - Clinical trials for Urinary Tract Infection Bacterial

Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae

TEMO-BLSE
Start date: January 1, 2015
Phase:
Study type: Observational

To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E UTI.